Director William Meury resigns from Syndax board to become Incyte CEO

Syndax Pharmaceuticals Inc

William Meury resigned from Syndax board effective June 24, 2025.
Meury accepted roles of President, CEO, and board member at Incyte Corporation.
Incyte is Syndax's collaboration partner for Niktimvo (axatilimab-csfr).
Resignation not due to any disagreement with Syndax's operations or policies.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.